NTQ5082 capsules 200 mg

DRUG3 trials

Sponsors

Nanjing Chia-tai Tianqing Pharmaceutical

Conditions

Paroxysmal Nocturnal HemoglobinuriaPrimary IgA Nephropathy

Phase 2

Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy

Not yet recruitingNCT06982040

Nanjing Chia-tai Tianqing PharmaceuticalPrimary IgA Nephropathy

Start: 2025-05-31End: 2026-09-30Target: 80Updated: 2025-05-21

Phase 3

A Long-term Efficacy and Safety of NTQ5082 Capsules

Not yet recruitingNCT07177872

Nanjing Chia-tai Tianqing PharmaceuticalParoxysmal Nocturnal Hemoglobinuria

Start: 2026-06-30End: 2028-06-30Target: 78Updated: 2025-09-17

A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

Not yet recruitingNCT07177859

Nanjing Chia-tai Tianqing PharmaceuticalParoxysmal Nocturnal Hemoglobinuria

Start: 2025-11-30End: 2026-11-30Target: 78Updated: 2025-09-17